Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
This study is ongoing, but not recruiting participants.
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Paul G. Richardson, MD, Dana-Farber Cancer Institute
First received: September 18, 2006
Last updated: June 11, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 2014|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|